请输入关键字:

热门搜寻:

GE Healthcare, Vanderbilt University Medical Center Partner for Safer, More Precise Immunotherapy Cancer Treatment

日期:2019年1月7日 上午9:58

Artificial Intelligence (AI)-powered applications will help predict how individual patients will respond to immunotherapies in advance of treatment
Partnership will enable identification of appropriate patients for immunotherapy clinical trials and treatment, reducing unnecessary and expensive trial failures and speeding up immunotherapy approvals

CHICAGO & NASHVILLE, Tenn.--()--GE Healthcare and Vanderbilt University Medical Center (VUMC) today announced a five-year partnership to enable safer and more precise cancer immunotherapies. Multiple diagnostic tools will be developed to help predict both the efficacy of an immunotherapy treatment and its adverse effects for a specific patient before the therapy is administered. This would allow physicians to better target immunotherapies to the right patients and avoid potentially damaging, ineffective and costly courses of treatments.

Immunotherapies use the immune system to recognize and attack cancer cells and can be more effective than traditional treatments, but response rates are often low and side effects can be severe1. GE Healthcare and VUMC will retrospectively analyze and correlate the immunotherapy treatment response of thousands of VUMC cancer patients, with their anonymized demographic, genomic, tumor, cellular, proteomic and imaging data. They will then develop AI-powered apps that draw on this data to help physicians identify the most suitable treatment for each individual patient.

Simultaneously, GE Healthcare and VUMC will develop new positron-emission tomography (PET) imaging tracers, which together with the apps, will help physicians to stratify cancer patients for clinical trials. It currently takes an average of 12 years2and costs almost $2bn3 to bring a drug to market. In many cases, inappropriate patients are recruited to participate in immunotherapy trials, incurring unnecessary expense and slowing down approvals of new therapies. It is hoped that the PET tracers will ultimately also be used to monitor the efficacy of immunotherapies in everyday practice.

“Immunotherapy offers tremendous promise but given the current unpredictability of some patients’ reactions to treatments, it is also associated with increased morbidity and cost. This partnership provides the opportunity to leverage strengths of both of our organizations to further personalize cancer care by creating new tools that allow clinicians to more accurately predict how patients will respond to a specific therapy,” said Jeff Balser, MD, PhD, President and Chief Executive Officer, Vanderbilt University Medical Center and Dean of the Vanderbilt University School of Medicine.

“GE Healthcare and Vanderbilt will combine their data science, genomic, imaging and cellular analysis capabilities to help improve clinical decision making. This partnership is a great example of the increasing convergence of the tools, technologies and data used by therapy innovators and healthcare providers,” said Kieran Murphy, President and Chief Executive Officer, GE Healthcare.

GE Healthcare and the Vanderbilt-Ingram Cancer Center, a world-renowned stem cell transplant facility, will also collaborate on methods to improve productivity, efficiency and cost of stem cell transplant processing operations by automating processes, digitizing workflows, improving throughput and industrializing operations.

The first analytics application prototype will be available by the end of 2019 and the PET tracer proof-of-concept by the end of 2020.

### END ###

About Vanderbilt University Medical Center 
Vanderbilt University Medical Center (VUMC) is one of the nation’s leading academic medical centers and is the largest comprehensive health system in Tennessee. Its core missions are the delivery of patient care, performing biomedical research and training future leaders in health care. VUMC is the recipient of top accolades by the National Academies, the Magnet Recognition Program, the Leapfrog Group, and has been named a Top Hospital by Truven Health Analytics 14 times. In 2018, U.S. News & World Report named VUMC to the ‘Honor Roll’ of the nation’s top 20 hospitals with 10 nationally-ranked adult specialty programs. In 2018, U.S. News also named the Monroe Carell Jr. Children’s Hospital at Vanderbilt among the nation’s ‘Best Children’s Hospitals’ with 10 out of 10 pediatric specialty programs nationally ranked. For more information and the latest news follow Vanderbilt Health on FacebookLinkedInTwitter, and in the VUMC Reporter.

About GE Healthcare 
GE Healthcare is the $19 billion healthcare business of GE (NYSE: GE). As a leading provider of medical imaging, monitoring, biomanufacturing, and cell and gene therapy technologies, GE Healthcare enables precision health in diagnostics, therapeutics and monitoring through intelligent devices, data analytics, applications and services. With over 100 years of experience in the healthcare industry and more than 50,000 employees globally, the company helps improve outcomes more efficiently for patients, healthcare providers, researchers and life sciences companies around the world. Follow us on FacebookLinkedInTwitter and The Pulse for latest news, or visit our website www.gehealthcare.com for more information.

These statements are not guarantees of future performance and undue reliance should not be placed on them.

__________________________ 
https://www.cancer.net/blog/2018-02/what-you-need-know-about-immunotherapy-side-effects
https://www.sciencedirect.com/science/article/pii/S2452302X1600036X
https://www2.deloitte.com/us/en/pages/life-sciences-and-health-care/articles/measuring-return-from-pharmaceutical-innovation.html

 

Contacts

GE Healthcare
David Morris
David.j.morris@ge.com
0044 7920 591370

Vanderbilt University Medical Center
John Howser
John.Howser@vumc.org
001 615-322-4747

 

GE Healthcare, Vanderbilt University Medical Center partner for safer, more precise immunotherapy cancer treatment (Photo: Business Wire)

Find online at https://ww2.mc.vanderbilt.edu/ (Graphic: Business Wire)

财华网所刊载内容之知识产权为财华网及相关权利人专属所有或持有。未经许可,禁止进行转载、摘编、复制及建立镜像等任何使用。

如有意愿转载,请发邮件至content@finet.com.hk,获得书面确认及授权后,方可转载。

更多精彩内容,请登陆
财华香港网(https://www.finet.hk/)
财华智库网(https://www.finet.com.cn)

现代电视(http://www.fintv.hk)

相關文章

1月4日
CTA基金会和AARP将举办由《创智赢家》主角Daymond John主持的现场比赛
1月4日
KidKraft任命Geoff Walker为新任总裁兼执行长
1月4日
武田注意到法院已批准与收购夏尔公司有关的协议计画
1月4日
武田宣布多项细胞疗法合作,以促进公司的新型免疫肿瘤学阵容
1月4日
可口可乐公司完成从Whitbread PLC手中收购Costa
1月4日
Immersion与Google达成下一代触觉设备开发协议
1月4日
香港航空、大阪机场和东京羽田机场2018年準点率在亚太区领先
1月4日
诺信EFD发布的全新“优化点胶”影片介绍了活塞如何改善製程控制
1月4日
光速中国创业投资基金喜获5.6亿美元承诺资本
1月4日
澳斯康生物完成4500万美元的A轮融资,以扩大一体化CMC,并在中国建设世界上最大的细胞培养生产厂

视频

快讯

12:35
中广核新能源(01811.HK)6月完成发电量同比减少9.6%
11:37
菲律宾财长:预计菲律宾未来两年将降息150个基点
11:15
【异动股】复合集流体板块拉升,英联股份(002846.CN)涨9.97%
11:15
【异动股】医疗服务板块下挫,健麾信息(605186.CN)跌5.23%
11:07
圣诺医药-B(02257.HK)料认购基金或录得重大亏损 已成立调查委员会
11:00
【异动股】房地产服务板块下挫,电子城(600658.CN)跌7.1%
10:57
余承东:享界S9开放配置选择 分为Ultra、Max两个版本
10:55
主力资金监控:领益智造净买入超3亿元
10:53
极兔速递(01519.HK)第二季包裹量同比增长30.7%
10:37
烧碱期货主力合约日内跌幅扩大至3%